CAS: 2430-27-5; 2-Propylpentanamide

该化合物是一种化学化合物,主要以其用于治疗癫痫和双极紊乱而闻名,主要以其用于治疗癫痫和双极紊乱而闻名,其特点是能够提高大脑内伽马-氨基丁酸(GABA)水平,从而促成其抗抽搐和情绪稳定效应.Valpromide通常被作为白色的脱白晶晶粉的白粉,在水中溶解,使之适合各种药物配方.其行动机制涉及...

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

2-cyano-2-propyl-valeric acid ethanol 2,2-dipropylmalononitrile valproyl chloride di-N-propyl acetonitrile valproic acid N-phenethyl-2-propylpentanamide benzyl 2-propylpentanoate

合成工艺路线路线简述

    2,2-二-正丙基乙酰基氯置于ammonium Hydroxide体系中,用 水,乙腈 用作溶剂,化学反应 2.0H,反应生成丙戊酰胺
    参考文献:丙戊酸类似物的新型酰胺和尿素衍生物的合成及抗痛觉过敏和抗惊厥活性的评价
    标题:丙戊酸类似物的新型酰胺和尿素衍生物的合成及抗痛觉过敏和抗惊厥活性的评价
    摘要:丙戊酸(vpa,1)是主要的广谱抗癫痫药和中枢神经系统药物,广泛用于治疗癫痫,双相情感障碍和偏头痛.Vpa的临床使用受到两种严重且危及生命的副作用,致畸性和肝毒性的限制.合成了许多vpa类似物及其酰胺,N-甲基酰胺和尿素衍生物,并在神经性疼痛和癫痫的动物模型中进行了评估.其中,两种酰胺和两种尿素衍生物(1)作为抗神经痛药的效价最高,酰胺(19和20)的ed 50值分别为49和51 Mg / Kg,尿素衍生物的ed 50值为49和74 Mg / Kg. (29和33).19,20,和29是等效于加巴喷丁,用于治疗神经性疼痛的主要药物.这些数据表明上述新型化合物作为用于治疗神经性疼痛的未来药物开发的候选物的巨大潜力.
    Doi:10.1021/jm901229S

    海关参考信息

    专利信息


    专利号:US-6630602-B1
    优先权日:1998-04-16
    标题 :Propylisopropyl acetic acid and propylisopropyl acetamide stereoisomers, a method for their synthesis and pharmaceutical compositions containing them
    发明人:BIALER MEIR; SPIGELSTEIN OFER; YAGEN BORIS
    权利人:YISSUM RES DEV CO
    摘要:The present invention relates to racemic propylisopropyl acetic acid and propylisopropyl acetamide and their isomers in their racemic and stereospecific forms, for use in treatment of neurological and psychotic disorders, and affective disorders and to treat pain, headaches and migraines. The isomers are of the compound formula I:wherein R1 is a methyl or ethyl group; R2 is H, methyl or an ethyl group; R3 is ethyl or a propyl group; and R4 is a hydroxyl or amide group; and the total number of carbon atoms in said compound is 8, provided that when R1 is a methyl group and R4 is an amide group, R2 and R3 are not ethyl, further provided that when R1 is an ethyl and R4 a hydroxyl group, only stereoisomers of the compound are referred to. The present invention further relates to a method for the stereoselective synthesis of the 2S and 2R stereoisomer of PID and PIA. The present invention also relates to pharmaceutical compositions containing as an active ingredient a racemic mixture or stereoisomers of the compounds of the general formula (I), which are useful for the treatment of neurological and psychotic disorders, and affective disorders and to treat pain, headaches and migraines.

    专利号:US-6969732-B2
    优先权日:1999-04-12
    标 题 :Propylisopropyl acetic acid and propylisopropyl acetamide stereoisomers, a method for their synthesis and pharmaceutical compositions containing them
    发明人:BIALER MEIR; SPIGELSTEIN OFER; YAGEN BORIS
    权利人:YISSUM RES DEV CO
    摘要:The present invention relates to racemic propylisopropyl acetic acid and propylisopropyl acetamide and their isomers in their racemic and stereospecific forms, for use in treatment of neurological and psychotic disorders, and affective disorders and to treat pain, headaches and migraines. The isomers are of the compound formula I n n R 1 is a methyl or ethyl group; R 2 is H, methyl or an ethyl group; R 3 is ethyl or a propyl group; and R 4 is a hydroxyl or amide group,n nand the total number of carbon atoms in said compound is 8, provided that when R1 is a methyl group and R4 is an amide group, R2 and R3 are not ethyl, further provided that when R1 is an ethyl and R4 a hydroxyl group, only stereoisomers of the compound are referred to.n nn The present invention further relates to a method for the stereoselective synthesis of the 2R stereoisomer of PID and PIA. The present invention also relates to pharmaceutical compositions containing as an active ingredient a racemic mixture or stereoisomers of the compounds of the general formula (I), which are useful for the treatment of neurological and psychotic disorders, and affective disorders and to treat pain, headaches and migraines.

    专利号:US-6417399-B1
    优先权日:1997-01-14
    标 题:Amelioration of neurological disorders by the administration of (2R),(3S), and/or (2S),3(S) stereoisomers of valnoctamide
    发明人:BIALER MEIR; YAGEN BORIS; SPIEGELSTEIN OFER; ROEDER MICHAEL; SCHURIG VOLKER
    权利人:YISSUM RES DEV CO
    摘要:The present invention generally relates to the individual stereoisomers of the drug valnoctamide (a mixture of four stereoisomer kinds, VCD-valmethamide or 2-ethyl-3-methyl pentanamide) useful in treatment of neurological and psychotic disorders such as different kinds of epilepsy and affective disorders, and useful as tranquilizers and to treat pain, and to pharmaceutical compositions containing, as an active ingredient, these stereoisomers. The present invention further relates to a method for stereoselective separation and quantification of the four stereoisomers from a racemic mixture of VCD or plasma of patients treated with the racemic drug. The present invention further relates to a unique method for the synthesis of the individual stereoisomers.

    专利号:US-2008214827-A1
    优先权日:2004-02-03
    标 题:Synthesis of Cyanoimino-Benzoimidazoles
    发明人:GOEHRING R RICHARD; WHITEHEAD JOHN; SHAO BIN
    权利人:EURO CELTIQUE SA
    摘要:Disclosed in certain embodiments is a process for synthesizing a compound of formula (V) and salts thereof.

    专利号:US-2002156320-A1
    优先权日:2000-01-13
    标 题 :Enantioselective synthesis of valproic acid analogues
    发明人:NAU HEINZ
    摘要:This invention employs camphorsultam as a chiral recoverable auxiliary to provide a new method for manufacturing valproic acid and valproic acid amides that facilitates the enantioselective or diasteroselective production of valproic acid analogs on a larger scale.

    专利号:CA-2555219-A1
    优先权日:2004-02-03
    标 题 :Synthesis of cyanoimino-benzoimidazoles
    湖北创联康成药物化学有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.hbclkc.com
    电话: 027-65388397👤
    📞湖北创联康成药物化学有限公司 ⚠️参考联系方式

    销售电话:027-65388397
    邮箱:3321478047@qq.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    郑州佰宇药业有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.zzbaiyu.com
    企业联系电话:13938569199👤
    📞郑州佰宇药业有限公司 ⚠️参考联系方式
    联系人:陈经理
    电话:13938569199


    邮箱:13938569199@163.com
    通信地址: 河南省郑州市新郑市龙湖镇小刘桥百鸿机电市场C3区22号
    邮编: 450000
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:河南省郑州市新郑市龙湖镇小刘桥百鸿机电市场C3区22号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: M H Subari IAA, Mutthumanickam G, Hj Jikal M, Shah MD, Tan JK, Tan YS, Palasubermaniam P, Palaniveloo K, Sathiya Seelan JS. LC-MS/MS profiling of the poisonous wild mushroom, Entoloma mastoideum, (Entolomataceae, Basidiomycota) in Sabah (Northern Borneo), Malaysia. Toxicon. 2024 Nov 28;251:108133. doi: 10.1016/j.toxicon.2024.108133. Epub 2024 Oct 18. 19(4):e0299198. doi: 10.1371/journal.pone.0299198.
    3: Delage C, Palayer M, Etain B, Hagenimana M, Blaise N, Smati J, Chouchana M, Bloch V, Besson VC. Corrigendum to "Valproate, divalproex, valpromide: Are the differences in indications justified?" [Biomed. Pharmacother., 158 (2023) 114051]. Biomed Pharmacother. 2023 Dec;168:115705. doi: 10.1016/j.biopha.2023.115705. Epub 2023 Oct 13. Erratum for: Biomed Pharmacother. 2023 Feb;158:114051. doi: 10.1016/j.biopha.2022.114051.
    63:102261. doi: 10.1016/j.legalmed.2023.102261. Epub 2023 Apr 17.

    合成参考文献


    参考文献:10.1007/bf01962697
    摘要:Nau H, Siemes H. Differentiation between valproate-induced anticonvulsant effect, teratogenicity and hepatotoxicity. Aspects of species variation, pharmacokinetics, metabolism and implications of structural specificity for the development of alternative antiepileptic agents such as delta 2-valproate. Pharm Weekbl Sci. 1992 Jun 19;14(3A):101–7. doi: 10.1007/bf01962697.
    参考文献:10.1007/bf00634242
    摘要:Dennis T, Curet O, Nishikawa T, Scatton B. Further evidence for, and nature of, the facilitatory GABAergic influence on central noradrenergic transmission. Naunyn Schmiedebergs Arch Pharmacol. 1985 Nov;331(2-3):225–34. doi: 10.1007/bf00634242.
    参考文献:10.1016/j.tiv.2008.04.009
    摘要:Luijten M, Verhoef A, Westerman A, Piersma AH. Application of a metabolizing system as an adjunct to the rat whole embryo culture. Toxicol In Vitro. 2008 Aug;22(5):1332–6. doi: 10.1016/j.tiv.2008.04.009.
    参考文献:10.1016/j.reprotox.2010.01.009
    摘要:Hettwer M, Reis-Fernandes MA, Iken M, Ott M, Steinberg P, Nau H. Metabolic activation capacity by primary hepatocytes expands the applicability of the embryonic stem cell test as alternative to experimental animal testing. Reprod Toxicol. 2010 Aug;30(1):113–20. doi: 10.1016/j.reprotox.2010.01.009.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知